Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...
Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
Camizestrant with a CDK 4/6 inhibitor significantly improves progression-free survival in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations. The SERENA-6 trial shows camizestrant's ...
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer ...
Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors Deidentified patient data from adults diagnosed with HER2– mBC between 2014 and 2022 were captured from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback